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Long term antiviral therapy with nucleos(t)ide analogs (NAs) may lead to the emergence of drug-resistance viral mutants in 
chronic hepatitis B virus (HBV) patient. The purpose of this study was to identify adefovir dipivoxil (ADV) resistance mutations 
of HBV polymerase and determine effective drugs to replace ADV. The reverse transcriptase (RT) coding region was PCR-amplified 
using HBV DNA extracted from patient blood samples and sequenced. Nineteen substitution mutations were detected. Among 
them, rtN238R, rtT240Y and rtN248H were often observed in patients receiving ADV administration. These three potential drug 
resistant sites were introduced into HBV replication-competent plasmids. The in vitro susceptibility of both wild-type (WT) and 
mutant-type (MT) HBV to NAs was analyzed by Southern blotting and quantitative real-time PCR. The rtN238R, rtT240Y and 
rtN248H substitutions had no obvious effect on HBV DNA replication or gene expression. The in vitro susceptibility analysis 
showed that rtN238R, rtT240Y and rtN248H substitutions were responsible for the reduced susceptibility to ADV, and demon-
strated a 5.42-, 2.89- and 5.72-fold increase in resistance towards ADV, respectively. However, HBV harbored these mutations 
retained normal susceptibility to LMV, LdT, ETV and TDF. 
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Hepatitis B virus (HBV) is a member of the hepadnavirus 
family and contains a 3.2 kb, relaxed circular (RC), partially 
double-stranded DNA genome [1,2] with four overlapping 
open reading frames (ORFs): P, S, C, and X [3]. HBV in-
fection can lead to acute and chronic necroinflammatory 
liver diseases, especially hepatocellular carcinoma (HCC), 
which account for half a million to 1.2 million deaths each 
year in the more than 350 million people who are chronic 
carriers of HBV [4–7]. HBV replicates through reverse tran-
scription of an RNA intermediate, called pregenomic RNA 
(pgRNA) [8]. Like retroviruses with an error-prone poly-
merase, such as human immunodeficiency virus (HIV), 
HBV has a quasispecies distribution in infected individuals 
[4,9]; virions with relevant resistance mutations can be select-
ed after treatment with nucleos(t)ide analogue (NA) drugs.  
To date, complete HBV eradication is seldom accom-
plished with currently available agents such as interferon 
and NAs [10]. Lamivudine (LMV), adefovir dipivoxil (ADV), 
entecavir (ETV), telbivudine (LdT) and tenofovir (TDF) are 
widely used for treatment of chronic hepatitis B (CHB) [11]. 
NA treatment inhibits HBV replication in patients and sig-
nificantly reduces mortality, the risk of cirrhosis-related com-
plications, and the incidence of hepatocellular carcinoma 
(HCC) [12]. However, the frequent emergence of drug-re-    
sistance mutations often leads to treatment failure and liver 
disease progression [13].  
Various drug-resistant mutations of HBV have been 
identified, all of which were located in the reverse tran-
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scriptase (RT) region of HBV polymerase, which is further 
divided into seven domains: A−G [14]. Resistance to LMV 
and LdT is conferred by mutations in the YMDD motif 
within the C domain. The most common mutations are 
rtM204I/V [15], which are usually accompanied with com-
pensatory mutations of rtL180M and/or rtV173L to restore 
HBV replication capacity [12,16,17]. An rtA181V/T or 
rtN236T substitution can reduce the anti-HBV effect of 
ADV [18]. Resistance to ETV requires a combination of 
mutations in the B, C, or D domain, such as rtI169T, 
rtM250I/V, and background substitutions at position rt204 
[12,19]. However, there has been no reported TDF re-
sistance mutation, except rtA194T which needs further con-
firmation [12,20–22].  
The present study focused on the analysis of HBV poly-
merase sequence variation from CHB patients to detect 
novel potential drug-resistance mutations. Analysis of HBV 
sequences from 5 CHB patients undergoing LMV and ADV 
alternate therapies identified many substitution mutations, 
including rtN238R, rtT240Y and rtN248H. These newly 
discovered mutations were then introduced into HBV repli-
cation-competent plasmids. In vitro analysis demonstrated 
that rtN238R, rtT240Y and rtN248H resulted in 5.61-, 2.76- 
and 5.71-fold increases in resistance toward ADV, respec-
tively. The results of the present study should provide cer-
tain specific references for clinical drug administration. 
1  Mateirals and methods 
(i) CHB patients and sequence analysis.  Serum samples 
from CHB patients receiving NA therapy were collected, 
from which HBV DNA was isolated using the QIAamp 
DNA Blood Mini Kit (Qiagen, Hilden, Germany). The 
HBV-RT segment was PCR-amplified with the primer pair: 
RT-F and RT-R (Table 1), and cloned into the pCR2.1 vec-
tor. Five clones of each PCR product were two-way sequenced   
Table 1  Primer sequences for the construction of MT HBV plasmids and 
qRT-PCRa) 








rtN238R-F CATTTA AACCCTCGCAAAACA AAG 552 
rtN238R-R CTTTGTTTTGCGAGGGTTTAAATG 730 
rtT240Y-F TAAACCCTAACAAATACAAGAGATG 548 
rtT240Y-R CATCTCTTGTATTTGTTAGGGTTTA 735 
rtN248H-F GGGTTACTCTCTACATTTTATGGGT 523 




a) MT, mutant; qRT-PCR, quantitative real-time PCR; F, forward; R, 
reverse; bold text, italics: substitution mutation for mutant HBV plasmids 
construction. 
and aligned with WT HBV (GenBank accession no. 
X02763.1, genome type A, subtype adw2). 
(ii) Plasmid constructs.  HBV mutants (MTs) were con-
structed using fusion-PCR with the primers listed in Table 1 
carrying aimed mutations and pHBV1.3 as a template, 
which is a replication-competent plasmid including 1.3-fold 
over-length HBV genotype A2 genome (GenBank accession 
no. X02763.1, subtype adw2) [23,24], with a pBluescript 
KS+backbone.  
(iii) NAs.  NAs including 2′,3′-dideoxy-3′-thiacytidine 
(LMV; Glaxo Smith Kline, Brentford, Middlesex, UK), 
ADV (Gilead Sciences, Foster City, CA, USA), ETV (Bristol- 
Myers Squibb Co., New York, NY, USA), LdT (Novartis 
Pharmaceuticals Canada Inc., Dorval, Quebec, Canada) and 
TDF (Gilead Sciences) were diluted according to the manu-
factures’ instructions and used in the assays at the indicated 
concentrations. 
(iv) Cell culture and transfection.  Hepatocellular car-
cinoma Huh7 cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM; Invitrogen, Carlsbad, CA, USA) 
at 37°C in a 5% CO2 atmosphere supplemented with 10% 
fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA), 2 
mmol L1 of glutamine, 100 IU mL1 of penicillin and 100  
IU m L1 of streptomycin [25]. Huh7 cells were seeded in 
6-well plates (1×106/well) and transfected with 2 g HBV- 
bearing plasmid per well using lipofectamine 2000 (Invitro-
gen) with or without the indicated NA concentrations. For 
transfection experiments, HBV-bearing plasmids were 
co-transfected with a SEAP expression vector into Huh7 
cells, the relative efficiency of transfections was assessed by 
measuring SEAP activity in the culture medium using a 
chemiluminescent detection method [26]. 
(v) Enzyme-linked immunosorbent assay (ELISA).  Huh7 
cells were transfected with the indicated HBV-bearing plas-
mids, hepatitis B surface antigen (HBsAg) and hepatitis B e 
antigen (HBeAg) in the supernatant at 96 h post transfection 
(hpt) were detected using a diagnostic kit (Shanghai Kehua 
Diagnostic Medical Products Co., Ltd., Shanghai, China) 
according to the manufacturer’s instructions [25].  
(vi) Western blotting.  Huh7 cells were transfected with 
the indicated HBV-bearing plasmids and harvested at 96 hpt. 
The protein concentrations were determined using the Bio- 
Rad protein assay kit (Bio-Rad Laboratories, Hercules, CA, 
USA). Total cell lysates (50 g) from the transfected cells 
were assayed by Western blotting by probing with an an-
ti-hepatitis B core antigen (HBcAg) antibody (Dako Cytoma-
tion Co., Carpinteria, CA, USA) and anti--actin (Beyotime 
Biotech Inc., Nantong, China), and detected by chemilumi-
nescence (SuperSignal West Pico; Thermo Scientific-Pierce 
Protein Biology Products, Rockford, IL, USA) followed by 
autoradiography and densitometry analysis using a secondary 
goat anti-mouse IgG HRP antibody (Jackson ImmunoResearch 
Laboratories, Inc., West Grove, PA, USA; diluted 1:10000) 
[27,28]. 
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(vii) Analysis of HBV DNA from intracellular core par-
ticles by Southern blotting.  Replication competent HBV 
WT/MTs plasmids were transfected into Huh7 cells. Total 
HBV DNA replicative intermediates from intracellular core 
particles were extracted and subjected to agarose gel elec-
trophoresis, followed by denaturation and Southern blotting 
with a 32P-labeled full length HBV probe according to pre-
viously published protocols [25,29]. Hybridization signals 
were visualized and analyzed using a phosphoimager (Cy-
clone, Packard Instrument Co., Inc., Meriden, CT, USA). 
Data were quantified with OptiQuant software (Packard 
Bioscience Co., Inc., Meriden, CT, USA). 
(viii) Quantitative real-time PCR (qRT-PCR).  Cell ly-
sates of Huh7 were treated with DNase I (Roche) at 37°C, 
30 min to digest input plasmid DNA. Total HBV DNA rep-
licative intermediates were purified from lysates of Huh7 
cells 96 hpt and were used as templates for qRT-PCR, 
which was conducted using SYBR Green I nucleic acid 
stain (Roche Diagnostics GmbH, Mannheim, Germany) on 
a Light Cycler real-time thermal cycler (Applied Biosys-
tems, Foster City, CA, USA) according to the manufactur-
ers’ instructions [29]. Primers HBV-RC-F and HBV-RC-R 
(Table 1) hybridized to the HBV surface gene were de-
signed to quantify HBV-DNA RC genomes (100 bp frag-
ment) by qRT-PCR relative to an external plasmid DNA 
standard [30].  
(ix) Statistical analysis.  The statistical analysis was 
carried out using GraphPad (GraphPad Software, San Diego, 
USA). Differences in multiple comparisons were deter-
mined for statistical significance using Student’s t-test. P< 
0.05 was considered as statistically significant. Results are 
presented as means ± SD. 
2  Results 
2.1  Sequence analysis of HBV-RT from CHB patients 
Five patients with lengthy CHB histories (>3 years) took 
part in this study. An increase in serum alanine aminotrans-
ferase (ALT) and HBV DNA levels indicated HBV varia-
tion. When resistance mutations to LMV or ADV (rtM204V/I 
for LMV, rtA181T/V and rtN236T for ADV) appeared 
along with the virologic breakthrough, which normally hap-
pened in 6−12 months treatment, a conversion therapy was 
carried out. The HBV-RT segment was PCR-amplified us-
ing HBV DNA extracted from the serum sample as a tem-
plate and sequenced. Sequence alignments with a reference 
indicated a variety of quasispecies in CHB patients after NA 
treatment, including rtS21A, rtL122F, rtN124F/H, rtP130Q, 
rtD131N, rtY135S/F, rtV142E, rtL145M, rtL180M rtA181V/T, 
rtS202G, rtM204V, rtF221Y, rtN236T, rtN238 R/H, rtT240Y, 
rtN248H, rtE263D and rtQ267H in the HBV-RT sequence 
(Figure 1) [31−33]. After LMV treatment, rtM204V and/or 
rtL180M mutations emerged as described in previous re-
ports [12,16,17]. Interestingly, a novel mutation, rtQ267H/R, 
was occasionally found after LMV therapy. Other than 
rtA181V and rtN236T, which occurred in all samples after 
about 12 months of ADV administration, we also commonly 
found the mutations rtN238R/H, rtT240Y and rtN248H, 
even though they did not appear in all samples (Figure 1). 
The frequencies of rtN238 and rtN248 (80%) substitutions 
were higher than that of rtT240 (40%) in different patients 
(Figure 1). The relatively high prevalence of these three 
substitutions in CHB patients with ADV therapy implies 
that they might be selected after ADV long-term usage and 
attenuate the anti-HBV effect of ADV.  
2.2  The replication capacity of MT pHBV1.3 in vitro 
To further analyze the influence of the rtN238, rtT240 and 
rtN248 mutations on HBV replication and sensitivity to 
ADV, three MT HBV replication-competent plasmids, 
pHBV-rtN238R, -rtT240Y and -rtN248H, were constructed 
based on pHBV1.3 [34]. The replication-competent plas-
mids were then transfected into Huh7 cells and pHBV1.3 
was used as a control. Southern blotting (upper panel) and 
subsequent densitometry analysis (lower panel) revealed no 
significant difference between the MT and parent HBV 
(Figure 2). There was a slightly lower HBV DNA level in 
MTs compared with the WT as determined by qRT-PCR, 
but they were not statistically different (Figure 2(b)). Thus, 
none of the substitutions had any obvious effect on HBV 
replication. 
HBsAg and HBeAg levels in culture supernatant at 96 
hpt were also measured by ELISA (Figure 2(c)), while 
HBcAg in cell lysates was analyzed by Western blotting 
(Figure 2(d)). The results indicated that the recombinant 
HBV with the substitution of rtN238R, rtT240Y or rtN248H, 
respectively, had similar expression levels as HBsAg, 
HBeAg and HBcAg with that of HBV WT. Taken together, 
the rtN238R, rtT240Y and rtN248H substitutions had no 
obvious effect on HBV DNA replication or gene expression 
under our experimental conditions.  
2.3  rtN238R, rtT240Y and rtN248H in HBV substitu-
tions are involved in reduced susceptibility to ADV 
In order to determine whether rtN238R, rtT240Y and 
rtN248H influenced HBV susceptibility to LMV and ADV, 
Huh7 cells were transfected with MT or WT HBV plasmids, 
then exposed to the indicated NA concentrations and the 
core-associated DNA was analyzed by Southern blotting. 
As shown in Figure 3(a), LMV inhibited the replication of 
MT and WT HBV in a dose-dependent manner. In contrast, 
ADV reduced WT HBV replication in a dose-dependent 
manner, but did not influence the three MT HBVs, indicat-
ing that MTs were less susceptible to ADV (Figure 3(b)). 
qRT-PCR targeted to HBV RC DNA was performed to 
calculate the increase in resistance of rtN238R, rtT240Y and 
rtN248H to ADV. The half maximal effective concentration  
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Figure 1  Sequence alignments of HBV RT regions. HBV DNA was isolated from serum samples of CHB patient (a), (b), (c), (d) and (e) who treated al-
ternately with LMV and ADV when the drug-resistance showed up. The HBV-RT segments were PCR-amplified and cloned. Five clones were sequenced 
for each sample. Then the sequences were aligned with the reference sequence (WT, GenBank accession no. X02763.1, genotype A). The region (rt167 to 
rt270) contained the substitution sites are shown.  
(EC50) of pHBV1.3-WT, -rtN238R, -rtT240Y and -rtN248H 
to ADV were about 1.38, 7.49, 3.99 and 7.90 mol L1, 
respectively, as calculated by qRT-PCR (Figure 4(b)), 
which was much higher than that of WT (1.38 mol L1). 
Their resistance indexes (the EC50 value of MT divided by 
that of WT) to ADV were about 5.42, 2.89 and 5.72, re-
spectively.  
2.4  rtN238R, rtT240Y and rtN248H substitutions main-
tained normal susceptibility to other NAs, but not ADV 
rtN238R, rtT240Y and rtN248H substitutions reduced the 
anti-HBV effect of ADV. We further analyzed their suscep-
tibility to other NAs. Huh7 cells were transfected with 
pHBV-rtN238R, -rtT240Y, -rtN248H or pHBV1.3 and then 
treated with indicated concentrations of LMV, ETV, LdT 
and TDF. qRT-PCR was used to measure the HBV RC- 
DNA copy number and the EC50 of WT and MT HBV to 
LMV (Figure 4(a)), ADV (Figure 4(b)), LdT (Figure 4(c)), 
ETV (Figure 4(d)) and TDF (Figure 4(e)). The EC50 values 
of pHBV-rtN238R, -rtT240Y, -rtN248H to LMV, LdT, 
ETV and TDF were all close to that of WT (1.08, 11.5, 0.79 
and 0.195 mol L1, respectively). The results indicated that 
rtN238R, rtT240Y and rtN248H decreased the susceptibility  
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Figure 2  Replication capacity and antigen expression levels of WT and HBV mutants. (a) Huh7 cells were transfected with WT or MT HBV plasmids. 
Encapsulated viral DNA was extracted and detected by Southern blotting (upper panel). Relaxed circular (RC), double stranded linear (DL) and single 
stranded (SS) HBV DNAs are indicated. The relative level of WT HBV replication capacity is shown as a percentage of the control by gray analysis (lower 
panel). (b) HBV RC DNA of mutants compared with that of WT HBV is shown as a percentage of the control. Each value is the mean of at least 3 inde-
pendent experiments. The error bars represent the standard deviation (SD). (c) HBsAg and HBeAg in the supernatant were detected using an ELISA diag-
nostic kit (Shanghai Kehua Diagnostic Medical Products Co., Ltd.) according to the manufacturer’s instructions. (d) Total lysates of Huh7 cells were pre-
pared and 50 μg of total protein was subjected to Western blotting. HBcAg was detected using mouse polyclonal antibody (upper panel) and β-actin was 
used as a loading control (lower panel).  
 
Figure 3  Southern blot analysis was used to detect the anti-HBV effect of LMV and ADV. Huh7 cells were transfected with pHBV1.3, pHBV-rtN238R, 
-rtT240Y and -rtN248H, and treated with LMV (a) and ADV (b) at the indicated concentrations. Core-associated HBV DNA was extracted from the cell 
lysates 96 hpt and subjected to agarose gel electrophoresis, followed by denaturation and Southern blotting.  
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of HBV to ADV, but they were still susceptible to LMV, 
LdT, ETV and TDF in vitro.  
3  Discussion 
HBV infection is a worldwide health problem. Chronic 
HBV infection can be treated with NAs, which are also 
widely used for HIV and herpes viruses [35,36], but drug 
resistance severely impaired HBV therapy. In the present 
study, we identified resistance mutations of HBV to ADV, 
which has been widely used together with LMV. Among the 
mutations found in patient blood samples, rtL180M, rtA-    
181V/T, rtS202G, rtM204V/I, and rtN236T were confirmed 
as NA resistance mutations, whereas rtS21A, rtL122F, 
rtN124F/H, rtP130Q, rtD131N, rtY135S/F, rtV142E, rtL145M, 
rtF221Y, rtE263D and rtQ267H were found in CHB patients 
[31−33,37,38] . Moreover, rtN238R, rtT240Y and rtN248H 
were regularly turned up in CHB patients with ADV treat-
ment, and they were introduced into replication- competent 
plasmids to demonstrate that they were also responsible for 
reduced susceptibility to ADV in vitro. 
NAs that mimic physiological nucleosides (dA/T/G/CTP) 
in terms of uptake and metamorphosis are incorporated into 
newly synthesized viral DNA giving rise to synthesis inhi-
bition and termination [39]. ADV showed comparative an-
tiviral activity against LMV-resistant HBV mutants and WT 
HBV [40]. However, in the first year of treatment, ADV 
resistance emerged in about 20% of LMV-resistant patients 
and in about 2% of patients with no LMV resistance-asso-     
ciated mutations [12,41], which may explain why so many 
ADV resistance-associated mutations were selected and 
found in the present study. A higher resistance equates to 
weaker selective pressure; hence, the frequency of rtN238R 
and rtN248H was higher than that of rtT240Y, in accord-
ance with the clinical data. Overall, according to our data, 
HBs/e/cAgs were not directly associated with HBV replica-
tion in vitro.  
HBV resistance mutations were all found in HBV-RT, 
with no exception for rtN238R (domain D), rtT240Y (do-
main D) and rtN248H (domain E). The HBV genome over-
laps, as the S gene is completely contained within the P 
gene and mutations in the HBV polymerase coding region 
may confer NA resistance that usually affects the HBsAg. 
However, rtN238R, rtT240Y and rtN248H substitutions had 
no influence on HBsAg secretion, because they all reside 
after the stop codon of the S gene.  
According to the three-dimensional (3D) HBV-RT 
structure predicted by SWISS-MODEL (http://swissmodel. 
expasy.org/), an automated protein modeling server, rtN238R, 
rtT240Y and rtN248H are situated close to residue M204 in 
the YMDD motif (data not shown), which was found to be 
the catalytic center for DNA synthesis. Substitutions may 
change the RT structure, and then prevent ADV from en-
tering the catalytic pocket or make ADV separate from the 
catalytic pocket easyly thereby reduce the anti-HBV effect 
of ADV.  
Fortunately, HBV mutants with any one of the rtN238R, 
rtT240Y or rtN248H substitutions retained normal suscepti-
bility to LMV, LdT, ETV and TDF. In further research, it 
will be interesting to test whether the combination of these 
three mutations enhances ADV resistance, and what will  
 
Figure 4  qRT-PCR was performed to detect the anti-HBV effect of 5 NAs. Huh7 cells were transfected with HBV-bearing plasmids, RC-DNA of encap-
sulated HBV DNA was extracted and analyzed by qRT-PCR to evaluate the antiviral effect of ADV (a), LMV (b), ETV (c), LdT (d) and TDF (e). The results 
shown were calculated as means ± 2 SDs (n=3).  
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happen when they are combined with rtA181V/T and/or 
rtN236T. Further, we plan to explore the susceptibility to 
NAs in hydrodynamically injected mice with replication- 
competent pAAV-HBV1.3. 
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